Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 480 Pleasant St Ste B300 WATERTOWN MA 02472-2468 |
Tel: | 1-212-3621200 |
Website: | https://eyepointpharma.com |
IR: | See website |
Key People | ||
Jay S. Duker President, Chief Executive Officer | Nancy S. Lurker Executive Vice Chairman of the Board | George Elston Chief Financial Officer, Executive Vice President |
Scott Jones Senior Vice President, Chief Commercial Officer | Dario A. Paggiarino Senior Vice President, Chief Medical Officer | Marcia Sellos-Moura Senior Vice President | Michael C. Pine Chief Corporate Development and Strategy Officer |
Business Overview |
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company's other products include YUTIQ, and DEXYCU. |
Financial Overview |
For the fiscal year ended 31 December 2023, Eyepoint Pharmaceuticals Inc revenues increased 11% to $46M. Net loss decreased 31% to $70.8M. Revenues reflect United States segment increase of 12% to $45.3M. Lower net loss reflects Impairment of acquired intangible assets decrease from $20.7M (expense) to $0K, Sales and marketing - Balancing value decrease of 52% to $11.4M (expense). |
Employees: | 121 as of Feb 29, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $489.66M as of Dec 31, 2023 |
Annual revenue (TTM): | $46.02M as of Dec 31, 2023 |
EBITDA (TTM): | -$74.60M as of Dec 31, 2023 |
Net annual income (TTM): | -$70.80M as of Dec 31, 2023 |
Free cash flow (TTM): | -$1.61M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 49,830,792 as of Mar 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |